SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis.

Joao GoncalvesGihyun MyungMinJeong ParkDeokyoon JeongJeehoon Ghil

Published in: Therapeutic advances in gastroenterology (2019)

ADL and SB5 show cross-immunogenicity in sera from patients with IBD or RA, supporting shared immune-dominant epitopes. ATI+ sera did not cross-react with SB5, suggesting different immunogenic epitopes between infliximab and SB5.

Keyphrases

rheumatoid arthritis
ulcerative colitis
patients with inflammatory bowel disease
disease activity
ankylosing spondylitis
interstitial lung disease
systemic sclerosis